

Datasheet for ABIN6699795

EGF Protein





Overview

| Quantity | 100 ug |
|---------------|----------------------------|
| Quantity: | 100 μg |
| Target: | EGF |
| Origin: | Human |
| Source: | Escherichia coli (E. coli) |
| Protein Type: | Recombinant |

Product Details

| Purpose: | Human Epidermal Growth Factor Recombinant Protein (Animal Free) |
|------------------------------|--|
| Purification: | Epidermal Growth Factor (EDF) is produced with no animal-derived raw products, animal free equipment and animal free protocols. Purity was determined to be greater than 95% as determined by analysis by HPLC, UV-Spectroscopy at 280nm, and by reducing and non-reducing SDS-PAGE. |
| Purity: | 95,00% |
| Endotoxin Level: | Measured by LAL is typically ≤ 1 EU/µg protein. |
| Grade: | Animal-Free |
| Biological Activity Comment: | The activity is determined by the dose-dependent proliferation of murine BALB/c 3T3 cells and is typically between 20-100 pg/mL. |

Target Details

| Target: | EGF |
|-------------------|--------------------|
| Alternative Name: | EGF (EGF Products) |

Target Details


| Background: | Synonyms: Urogastrone, URG |
|---------------------|---|
| | Background: Epidermal Growth Factor (EGF) is a growth factor that stimulates the proliferation |
| | of epithelial and epidermal cells. EGF family members are characterized by three intramolecula |
| | disulfide bonds and can bind to four different receptor tyrosine kinases known as EGFR/ErbB1, |
| | ErbB2, ErbB3, and ErbB4. Recombinant human EGF is a single, non-glycosylated protein |
| | containing 53 amino acids, with a molecular weight of 6.2 kDa. |
| UniProt: | P01133 |
| Pathways: | NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling |
| | Pathway, Neurotrophin Signaling Pathway, Regulation of Carbohydrate Metabolic Process, |
| | Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, |
| | Thromboxane A2 Receptor Signaling, EGFR Downregulation |
| Application Details | |
| Application Notes: | Other: User Optimized |
| | Application_Note: Epidermal Growth Factor Recombinant Protein has been tested by biological |
| | activity and is suitable as a control for polyclonal or monoclonal anti-Epidermal Growth Factor |
| | in immunological assays. |
| Comment: | Suggested_Applications: Cellular Assay |
| | Other_Performance_Data: |
| Restrictions: | For Research Use only |
| Handling | |
| Format: | Lyophilized |
| Reconstitution: | Reconstitution_Buffer: Restore with deionized water (or equivalent) |
| | Reconstitution_Volume: 1.0 mL |
| Concentration: | 0.1 mg/mL |
| Buffer: | Buffer: 0.1 % Trifluoroacetic acid |
| | Stabilizer: None |
| Preservative: | Without preservative |
| Storage: | -20 °C |
| Storage Comment: | Store vial at -20° C prior to restoration. Dilute only prior to immediate use. Maintain sterility. This |

product DOES NOT contain preservative. DO NOT VORTEX. We recommend adding a carrier protein such as HSA or BSA to 0.1% (i.e. 1.0 mg/mL). For best results aliquot contents and freeze at -20° C or colder. Avoid cycles of freezing and thawing. Centrifuge vial before each opening to dislodge contents from the cap and to clarify if contents are not clear after standing at room temperature.

Expiry Date:

6 months

Images



SDS-PAGE

Image 1. SDS-PAGE of Human Epidermal Growth Factor Recombinant Protein (Animal Free) Bioactivity of Human Epidermal Growth Factor Recombinant Protein. 3T3 cells were cultured with 0 to 1 ng/mL Human EGF. Cell proliferation was measured after 44 hours and the linear portion of the curve was us used to calculate the ED50. The ED50 of Human EGF is 8.8-13.2 pg/mL. This value is comparable to the typical expected range of 20-100 pg/mL.